Cabaletta Bio is a biotechnology business based in the US. Cabaletta Bio shares (CABA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.82 – a decrease of 1.62% over the previous week. Cabaletta Bio employs 154 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.82 |
|---|---|
| 52-week range | $1.59 - $19.06 |
| 50-day moving average | $2.25 |
| 200-day moving average | $4.68 |
| Wall St. target price | $20.60 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.16 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.82 from 2025-03-14
| 1 week (2025-03-07) | -1.62% |
|---|---|
| 1 month (2025-02-14) | -32.84% |
| 3 months (2024-12-17) | -33.82% |
| 6 months (2024-09-17) | -56.56% |
| 1 year (2024-03-15) | -90.29% |
|---|---|
| 2 years (2023-03-16) | -76.52% |
| 3 years (2022-03-16) | 6.43% |
| 5 years (2020-03-16) | 7.01 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -37.9% |
| Return on equity TTM | -62.16% |
| Profit margin | 0% |
| Book value | $3.57 |
| Market Capitalization | $87 million |
TTM: trailing 12 months
We're not expecting Cabaletta Bio to pay a dividend over the next 12 months.
Over the last 12 months, Cabaletta Bio's shares have ranged in value from as little as $1.59 up to $19.0599. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cabaletta Bio's is 2.58. This would suggest that Cabaletta Bio's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Cabaletta Bio, Inc. , a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co. , Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc.
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Check out the best-performing ETFs so far in 2025.